• INCLUSION CRITERIA:

• Participants must have a documented diagnosis of MM defined by the IMWG Criteria. Participants at diagnosis must have had a serum M-protein >= 3 g/dL and/or bone marrow plasma cells >= 10% and at least one of the following:

  • Anemia: Hemoglobin <=10 g/dL, or
  • Renal Failure: serum creatinine >= 2.0 mg/dL, or
  • Hypercalcemia: Ca >= 10.5 mg/dL, or
  • Lytic bone lesions on X-ray, CT, or PET/CT, or
  • >= 2 focal lesions on spinal MRI, or
  • >= 60% bone marrow plasma cells, or
  • Involved/un-involved serum free light chain ration >= 100

• Participants must have measurable disease defined by any one of the following:

  • Monoclonal bone marrow plasma cells > 5%
  • Serum monoclonal protein >= 0.2 g/dl
  • Urine monoclonal protein > 200 mg/24 hr
  • Serum immunoglobulin free light chain > 10 mg/dL AND abnormal kappa/lambda ratio
  • A measurable lesion on PET/CT or MRI

• Participants fit criteria for one of the following categories:

  • Newly diagnosed multiple myeloma (NDMM)
  • Relapsed and/or refractory multiple myeloma (RRMM) with at least 1 prior line of therapy

• Age >=18 years.

• ECOG performance status <= 2

• Negative serum or urine pregnancy test at screening for WOCBP.

• Women of child-bearing potential and men must agree to use effective contraception (hormonal or barrier method of birth control; abstinence) 24 hours prior to and for the 24 hours after each 18F-fluciclovine administration.

• Ability of subject to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to 18F-FDG
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to 18F-fluciclovine or other similar agents.
• Subjects with severe claustrophobia unresponsive to oral anxiolytics or unwilling to take them.
• Uncontrolled intercurrent illness including, psychiatric illness/social situations that would limit compliance with study requirements.
• Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with 18F-fluciclovine, breastfeeding should be discontinued if the mother is treated with 18F-fluciclovine until 3 days after 18F-fluciclovine.